This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

Anti-oncogenic drugs - In order to grow, tumor cells produce chemical growth factors by switching on oncogenes. Many tumors rely on a mutation of the RAS oncogene in order to develop. Scientists ...

Problems arise, however, when mutations convert the proto-oncogene to an oncogene, rendering Ras permanently active regardless of the signals the cell receives. How do tumor suppressors differ?

We discovered one of the major ways by which RAS oncogenes cause normal cells to become cancerous – and identified new targets for cancer treatment. Scientists at The Institute of Cancer Research led ...

(A) Oncogene mutations were grouped together when ... (B) Incidence of BRAF mutations and co-occurring mutations in any RAS gene. (C) Incidence of co-occurring KRAS and PIK3CA mutations.

RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA ...